Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRETTO-531 selpercatinib versus cabozantinib or vandetanib in RET-mutant medullary thyroid cancer
NL-OMON49573Phase 3Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of selpercatinib, cabozantinib and vandetanib in Medullary Thyroid Cancer (MTC) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Treatment failure-free survival by blinded independent central review. Planned start Mar 2020; status: withdrawn.
02
Drugs
selpercatinibcabozantinibvandetanib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NL-OMON49573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49573.